Your browser doesn't support javascript.
loading
Triptolide activates the Nrf2 signaling pathway and inhibits the NF-κB signaling pathway to improve Alzheimer disease.
He, Zuoting; Botchway, Benson O A; Zhang, Yong; Liu, Xuehong.
Afiliação
  • He Z; Department of Histology and Embryology, School of Medicine, Shaoxing University, Zhejiang, Zhejiang Province, 312000, China.
  • Botchway BOA; Institute of Neuroscience, Zhejiang University School of Medicine, Hangzhou, China.
  • Zhang Y; Bupa Cromwell Hospital, Kensington, London, UK.
  • Liu X; Department of Histology and Embryology, School of Medicine, Shaoxing University, Zhejiang, Zhejiang Province, 312000, China.
Metab Brain Dis ; 39(1): 173-182, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37624431
ABSTRACT
Alzheimer disease (AD) is a common neurodegenerative disease with pathological features of accumulated amyloid plaques, neurofibrillary tangles, and the significant inflammatory environment. These features modify the living microenvironment for nerve cells, causing the damage, dysfunction, and death. Progressive neuronal loss directly leads to cognitive decline in AD patients and is closely related to brain inflammation. Therefore, impairing inflammation via signaling pathways may facilitate either the prevention or delay of the degenerative process. Triptolide has been evidenced to possess potent anti-inflammatory effect. In this review, we elaborate on two signaling pathways (the NF-κB and Nrf2 signaling pathways) that are involved in the anti-inflammatory effect of triptolide.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenantrenos / Doenças Neurodegenerativas / Diterpenos / Doença de Alzheimer Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fenantrenos / Doenças Neurodegenerativas / Diterpenos / Doença de Alzheimer Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article